Inhibitors of phosphodiesterase 4 (PDE 4): A new therapeutic option in the treatment of psoriasis vulgaris and psoriatic arthritis

J Dermatolog Treat. 2015;26(4):326-8. doi: 10.3109/09546634.2014.991267. Epub 2014 Dec 29.

Abstract

Psoriasis vulgaris and psoriatic arthritis are inflammatory diseases in which inflammation and sustained inducing lesions result from immune disorders associated with overactivity of T cells that produce multiple proinflammatory cytokines, including tumor necrosis factor alpha (TNF-α) and interleukin (IL): IL-2, IL-12, IL-17, IL-22 or IL-23. Modern treatment of these diseases is focused on reducing the inflammatory process responsible for the development of the disease. In recent years, the treatment of psoriasis is developing at a dynamic rate. Such therapeutic advances are contributed to the possibility of patient therapy through the use of some registered biologic agents, such as TNF-α inhibitors (infliximab, etanercept and adalimumab), and an inhibitor of the p40 subunit common to IL-12 and IL-23 (ustekinumab). In addition to the already registered medications for the indications mentioned above, there is a large group of preparations that are currently undergoing clinical trials in Europe, Canada and the United States, which provides hopes of therapy efficacy and safety.

Keywords: Apremilast psoriasis vulgaris; inhibitors of phosphodiesterase; psoriasis arthritis.

Publication types

  • Review

MeSH terms

  • Arthritis, Psoriatic / drug therapy*
  • Cyclic Nucleotide Phosphodiesterases, Type 4 / drug effects
  • Humans
  • Interleukins / immunology
  • Phosphodiesterase 4 Inhibitors / therapeutic use*
  • Psoriasis / drug therapy*
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors

Substances

  • Interleukins
  • Phosphodiesterase 4 Inhibitors
  • Tumor Necrosis Factor-alpha
  • Cyclic Nucleotide Phosphodiesterases, Type 4